Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on July 12, 2018, covering events occurring between July 12 and July 16, 2018. The filing details significant executive leadership changes, specifically the appointment of a new Chief Financial Officer (CFO) and Chief Scientific Officer (CSO), and the resignation of the former CFO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Compensation
Chief Financial Officer Transition
- Resignation: Mariam E. Morris resigned as CFO effective July 12, 2018. The resignation was not related to any disagreement with the Company.
- Separation Terms for Ms. Morris:
- 12 months of continued base salary payments.
- Immediate vesting of all unvested stock options.
- COBRA premium payments for up to 12 months.
- Waiver of non-compete covenant.
- 30-day consulting period to aid transition.
- Appointment of Joseph M. Miller: Effective July 12, 2018.
- Base Salary: $320,000 per year.
- Target Bonus: 40% of base salary.
- Equity Grants: 105,000 stock options (4-year vest) and 45,000 restricted stock units (4-year vest).
- Severance: 12 months of base salary, prorated bonus, and full option vesting upon termination without Cause or for Good Reason.
Chief Scientific Officer Appointment
- Appointment of Dr. Pericles Calias: Effective July 16, 2018.
- Base Salary: $260,000 per year.
- Target Bonus: 40% of base salary.
- Equity Grants: 80,000 stock options (4-year vest).
- Severance: 12 months of base salary, prorated bonus, and full option vesting upon termination without Cause or for Good Reason.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of business risks. The primary risk disclosed relates to the transition of key financial and scientific leadership, though the Company notes the former CFO's resignation was amicable and includes a transition consulting period.
Investor Verification Checklist
- Verify the exact vesting schedules and performance conditions for the 105,000 options and 45,000 RSUs granted to Joseph M. Miller.
- Confirm the total number of unvested options held by Mariam E. Morris that were accelerated upon her departure.
- Review the full text of the employment agreements (Exhibits 10.1, 10.2, and 10.3) for specific definitions of "Cause" and "Good Reason."
- Assess the impact of these executive changes on the Company's ongoing drug development programs and financial reporting capabilities.